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Background: B-Cell chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the United
States. Clinical treatment of CLL is often limited due to drug resistance and severe therapy-induced toxicities. We
hypothesized that the omega 3 (n-3) fatty acids, eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA),
would increase the sensitivity of malignant B-lymphocytes to anti-cancer drugs doxorubicin, vincristine and/or
fludarabine in vitro and that increased sensitivity is achieved by alterations in cell-cycle progression leading to
growth inhibition and/or enhanced cell death. We further postulate that enhanced sensitivity is dependent on the
formation of lipid peroxides and to the generation of reactive oxygen species (ROS).
Methods: In the present study, B-CLL-derived leukemic cell lines EHEB and MEC-2 and the B-Prolymphocytic
leukemic-derived (PLL) cell line JVM-2 were tested for in vitro sensitivity against doxorubicin, vincristine or
fludarabine in the presence or absence of vehicle, arachidonic acid (omega 6), EPA or DHA. Cell cycle analysis and
Annexin-V assays were performed to determine cell cycle progression and % apoptotic cells, respectively. Assays for
malondialdehyde, a measure of lipid peroxidation, and DCF fluorescence assays, a measure of intracellular ROS,
were performed to determine if enhanced sensitivity of cells to the drugs by n-3 was dependent on the formation
of ROS.
Results: Our results indicated that: 1) EPA and DHA differentially sensitized B-leukemic cell lines EHEB, JVM-2 and
MEC-2 to doxorubicin, vincristine and fludarabine in vitro; 2) n-3 alone and with drug treatment increased cell death
and induced G2/M arrest in a cell-type specific manner; 3) lipid peroxidation increased in the presence of n-3; 4)
there was higher lipid peroxidation in MEC-2 cells in presence of DHA and doxorubicin than with either alone; 5)
n-3 increased generation of ROS in MEC-2, and 6) the addition of vitamin-E abrogated the increase in ROS
generation and chemo-sensitivity of MEC-2 to doxorubicin by DHA.
Conclusion: N-3’s are promising chemo-sensitizing agents for the treatment of CLL. Selective enhancement of
chemo-sensitivity of EHEB, JVM-2 and MEC-2 to drugs by n-3 that is not dependent on increased lipid peroxidation
and ROS generation indicates alternative mechanisms by which n-3 enhances chemo-sensitivity.
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B-Cell chronic lymphocytic leukemia (CLL) is the most
common form of leukemia in the United States [1]. CLL
is a disease of the elderly with two thirds of patients
being over 65 years of age at time of diagnosis [1]. CLL
remains largely incurable outside of allogeneic trans-
plantation [1]. Despite the success of current treatments
such as fludarabine, many patients develop drug resist-
ance and disease relapse [2]. As such, clinical treatment
of CLL is often hindered by drug resistance and the
non-selectivity of most drugs [3]. Additionally, treatment
options for CLL patients who require aggressive treat-
ment are limited due to significant side-effect profiles
which are often too toxic for the elderly or those with
comorbidities [1]. Given the age group of patients diag-
nosed with CLL, a therapeutic intervention that can
increase the sensitivity of CLL cells to chemotherapy
without causing additional adverse effects would be cli-
nically beneficial.
Omega 3 and omega 6 polyunsaturated fatty acids
(PUFAs) are essential fatty acids (FAs) which must be
obtained from diet. Long chain omega 3 fatty acids
(eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA)) are primarily found in fish oils [4]. The omega 6
fatty acid, arachidonic acid (AA), is primarily found in the
meat of animals that consumed corn or soybeans. The ra-
tio of omega 3 FAs to omega 6 FAs in the average western
diet is heavily weighted in favor of omega 6 [5,6]. Omega
3 fatty acids have consistently been shown to enhance sen-
sitivity of various solid tumor cells to chemotherapy
in vitro [7,8] and in vivo [9-11]. However, it has not been
shown whether n-3 can enhance the sensitivity of CLL to
anti-cancer drugs.
Previous studies performed by our group have shown
that consumption of an omega 3 supplement, predomin-
antly composed of EPA and DHA, increased the sensitivity
of malignant B lymphocytes isolated from patients with
early CLL (RAI stages 0, 1) to doxorubicin in an in vitro
assay [12]. These findings prompted us to further evaluate
the potential use of omega 3 as a chemo-sensitizing agent
for the treatment of CLL. The primary objective of this
study was to determine whether EPA and/or DHA could
increase the sensitivity of malignant B-lymphocytes to
doxorubicin, vincristine and/or fludarabine in vitro. Se-
condary objectives were to elucidate potential mechanism
(s) by which n-3 enhance chemo-sensitivity. We hypothe-
sized that EPA and/or DHA would increase the sensitivity
of malignant B-lymphocytes to doxorubicin, vincristine
and fludarabine in vitro and that enhanced sensitivity is
mediated by alterations in cell cycle progression leading to
enhanced growth inhibition and/or enhanced cell death.
We further postulate that increased chemo-sensitivity is
dependent, in part, on the formation of lipid peroxides,
and the generation of reactive oxygen species (ROS).In this study we assayed for: 1) fatty acid lipid compo-
sition, 2) in vitro sensitivity of B-CLL-derived cell lines
EHEB, and MEC-2 and B-Prolymphocytic-derived (PLL)
cell line JVM-2 against doxorubicin, vincristine and
fludarabine in the presence of vehicle (no added FA),
AA, EPA or DHA, 3) % of apoptotic cells, 4) cell cycle
distribution, 5) generation of intracellular reactive oxy-
gen species (ROS), and 6) levels of lipid peroxidation.
Results
N-3 and N-6 fatty acids induce cell death
Figures 1A-C illustrates the % alive cells ± SEM of EHEB,
JVM-2 and MEC-2 following treatment with vehicle, or
increasing concentrations of AA, EPA and DHA. Cell
viability was assessed by Trypan Blue Exclusion assay
following treatment for 72 hours. Treatment with AA,
EPA or DHA induced dose-responsive reductions in cell
viability as compared to vehicle in all three cell lines.
We wanted to determine the chemo-sensitizing effects
of FA following treatment with concentrations of FA
that alone did not induce significant cytotoxicity. Thus,
we chose to use concentrations of AA at 25 μM, 35 μM
and 25 μM, EPA at 50 μM (all cell lines) and DHA at
75 μM, 50 μM and 50 μM for EHEB, JVM-2 and MEC-2,
respectively. The chosen FA concentrations used in this
study are clinically achievable [12]. Gas chromatography
post 72 hour of FA treatment validated FA incorporation
in all cells (Supplementary Data-1).
EPA and DHA differentially sensitize malignant
B-lymphocytes to doxorubicin, vincristine and fludarabine
in vitro
In our study, we wanted to determine whether FA pre-
treatment would synergistically increase the cytotoxic ef-
fects (greater effect than the sum effect due to FA and
drug individually) of anti-cancer drugs doxorubicin, vin-
cristine or fludarabine on three different B-leukemic
cells. Thus, all measurements obtained from the MTT
assay following treatment with the anti-cancer drug in
the presence of vehicle, or FA were compared to cells
treated with vehicle or FA only.
Figure 2A illustrates the in vitro sensitivity of EHEB to
doxorubicin (0–7.5 μM) in the presence or absence of
vehicle, AA, EPA or DHA. Compared to vehicle, cell via-
bility was significantly reduced in cells pre-treated with
either EPA or DHA but not with AA when treated with
doxorubicin.
Figure 2B illustrates the in vitro sensitivity of EHEB to
fludarabine (0-50 μM) in the presence or absence of ve-
hicle, AA, EPA or DHA. Compared to vehicle, cell via-
bility was significantly reduced in cells pre-treated with
EPA when treated with fludarabine (30 μM and 40 μM).
However, there was no difference in the sensitivity of
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Figure 1 Determination of optimal FA concentrations. Figure 1A-C illustrates the mean % live cells ± SEM of EHEB, JVM-2 and MEC-2
following 72 hour treatment with vehicle, or increasing concentrations of AA, EPA or DHA. Percent (%) live cells was determined after 72 hour
treatments by trypan blue exclusion assay. Figure 1A illustrates the mean % live cells ± SEM of EHEB following treatment with vehicle, or
increasing concentrations of AA, EPA or DHA. Significant reductions in % live cells were observed at 55 μM AA, 75 μM and 100 μM EPA, and
100 μM DHA as compared to vehicle. Although not statistically significant, concentrations of AA 35 μM and AA 45μM indicated viabilities of 57%
and 54%. FA concentrations of AA 25 μM, EPA 50 μM and DHA 75 μM were chosen for the remainder of the study. Figure 1B illustrates the mean
% live cells ± SEM of JVM-2 following treatment with vehicle, or increasing concentrations of AA, EPA or DHA. Significant reductions in % live cells
were observed at 45 μM and 55 μM AA, and 75 μM and 100 μM EPA as compared to vehicle. Although not statistically significant, concentrations
of DHA 75 μM and DHA 100 μM indicated cell viabilities of 65% and 55%. FA concentrations of AA 35 μM, EPA 50 μM and DHA 50 μM were
chosen for the remainder of the study. Figure 1C illustrates the mean % live cells ± SEM of MEC-2 following treatment with vehicle, or increasing
concentrations of AA, EPA or DHA. Significant reductions in % live cells were observed at 45 μM AA, 75 μM and 100 μM EPA and 75 μM and
100 μM DHA as compared to vehicle. FA concentrations of AA 25 μM, EPA 50 μM and DHA 50 μM were chosen for the remainder of the study.
Statistical significant was determined by Multiple Comparison Test using Tukey’s correction. Abbreviations: AA- arachidonic acid, EPA- eicosapentaenoic
acid, DHA- docosahexaenoic acid, α = 0.05, * <0.05, ** < 0.01, *** < 0.001.
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treatment had a non-significant slightly protective effect
on EHEB cells treated with fludarabine.
Compared to vehicle, pre-treatment with AA, EPA or
DHA did not significantly change the sensitivity of
EHEB to vincristine (data not shown).
In our model, an increase in chemo-sensitivity of cells
to the drug by FA can be mediated by both enhanced
cell death and/or enhanced growth-inhibition. To deter-
mine whether the decreases in cell viability seen in the
MTT assays were a result of enhanced cell death or of
growth-inhibition we performed an Annexin-V assay.
Figure 2C illustrates the % dead EHEB cells (± SEM)
in the presence or absence of vehicle, AA, EPA, or DHA
alone and after treatment with doxorubicin (1.5 μM) or
fludarabine (40 μM). The concentration of doxorubicin
(1.5 μM) was chosen as this concentration induced a sig-
nificant difference in cell viability between FA and vehicle
pre-treated cells and because this concentration is clini-
cally achievable [13]. The concentration of fludarabine
(40 μM) was chosen as this concentration induced the
greatest significant difference in cell viability between EPA
and vehicle pre-treated cells (Figure 2B); however, this
concentration is ~5-10 times greater than the peak plasma
concentration of fludarabine [14]. Compared to vehicle,
cells pre-treated with DHA, but without drug, had signifi-
cantly higher cell death. The addition of doxorubicin or
fludarabine to DHA pre-treated cells significantly increasedcell death as compared to vehicle and drug treatment. Cell
death was mediated predominately through apoptosis
(Figure 2C). In cells treated with doxorubicin or
fludarabine, pre-treatment with either AA or EPA did not
increase cell death as compared to vehicle. Figure 2D dis-
plays a graphical 2D representation of Annexin-V/PI plots
of EHEB cells pre-treated with either vehicle or DHA and
following treatment with doxorubicin or fludarabine.
Figure 3A illustrates the in vitro sensitivity of JVM-2
to doxorubicin (0–7.5 μM) in the presence or absence of
vehicle, AA, EPA or DHA. Compared to vehicle, all FA
pre-treatment significantly decreased cell viability due to
doxorubicin treatment.
Figure 3B illustrates the in vitro sensitivity of JVM-2
to vincristine (0-250 nM) in the presence or absence of
vehicle, AA, EPA or DHA. Compared to vehicle, only
DHA pre-treatment significantly decreased cell viability
due to vincristine treatment.
Pre-treatment with AA, EPA or DHA did not induce
any significant differences in the sensitivity of JVM-2 cells
to fludarabine (data not shown).
Figure 3C illustrates the % dead JVM-2 cells (± SEM)
in the presence or absence of vehicle, AA, EPA, or DHA
alone and following treatment with doxorubicin
(1.5 μM) or vincristine (100 nM). The concentration of
vincristine (100 nM) was chosen as this concentration
induced a significant difference in cell viability between
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Figure 2 In vitro sensitivity of EHEB following treatment with doxorubicin or fludarabine in the presence and absence vehicle, AA, EPA
or DHA. Cell viability was determined by MTT assay. Percent (%) cell death was determined by Annexin-V/Propidium Iodide duel stain with flow
cytometry. Figure 2A illustrates the % cell viability ± SEM of EHEB to doxorubicin (0–7.5 μM) in the presence or absence of vehicle, AA 25 μM, EPA
50 μM or DHA 75 μM. Cells pre-treated with either EPA or DHA had significantly greater decreases in cell viability as compared to vehicle when
treatment with doxorubicin. Figure 2B illustrates the % cell viability ± SEM of EHEB to fludarabine (0-50 μM) in the presence or absence of vehicle,
AA 25 μM, EPA 50 μM or DHA 75 μM. Pre-treatment of cells with EPA had significantly greater reductions in cell viability as compared to vehicle
when treated with 30 μM and 40 μM fludarabine. Figure 2C illustrates the % dead cells ± SEM of EHEB following pre-treatment with vehicle,
AA 25 μM, EPA 50μM or DHA 75 μM alone and following treatment with 1.5 μM doxorubicin or 40 μM fludarabine. Pre-treatment with DHA
alone induced significantly greater cell death as compared to vehicle. Compared to vehicle, cells pre-treated with DHA had significantly higher
cell death when treated with doxorubicin or fludarabine. Figure 2D provides 2D graphical representations of Annexin-V/PI Plots. ‘Early’ Apoptosis
was defined as cells positive for Annexin-V-FITC only. ‘Late’ Apoptosis was defined as cells positive for Annexin-V-FITC and PI. ‘Necrotic’ was
defined as cells positive for PI only. Statistical significance was determined by Multiple Comparison Test with Dunnet’s correction (Figure 2A and
B) or Tukey’s correction (Figure 2C). α = 0.05, * <0.05, ** < 0.01, *** < 0.001.
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vehicle, pre-treatment with DHA alone induced signifi-
cant cell death. Pre-treatment with DHA significantly in-
creased cell death due to either doxorubicin or
vincristine treatment. Figure 3D displays a graphical 2D
representation of Annexin-V/PI plots of JVM-2 cells
pre-treated with either vehicle or DHA and following
treatment with doxorubicin or vincristine.Figure 4A illustrates the in vitro sensitivity of MEC-2
to doxorubicin (0–7.5 μM) in the presence or absence
of vehicle, AA, EPA or DHA. Compared to vehicle,
pre-treatment with either EPA or DHA significantly
decreased cell viability due to doxorubicin treatment.
Figure 4B illustrates the in vitro sensitivity of MEC-2
to vincristine (0-250 nM) in the presence or absence of
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Figure 3 In vitro sensitivity of JVM-2 following treatment with doxorubicin or vincristine in the presence and absence vehicle, AA, EPA
or DHA. Cell viability was determined by MTT assay. Percent (%) cell death was determined by Annexin-V/Propidium Iodide duel stain with flow
cytometry. Figure 3A illustrates the % cell viability ± SEM of JVM-2 to doxorubicin (0–7.5 μM) in the presence or absence of vehicle, AA 35 μM,
EPA 50 μM or DHA 50 μM. Cells pre-treated with AA, EPA or DHA induced significantly greater decreases in cell viability as compared to vehicle
when treated with doxorubicin. Figure 3B illustrates the % cell viability ± SEM of JVM-2 to vincristine (0-250 nM) in the presence or absence of
vehicle, AA 35 μM, EPA 50 μM or DHA 50 μM. Compared to vehicle, only cells pre-treated with DHA had significantly greater reductions in cell
viability when treatment with vincristine. Figure 3C illustrates the % dead cells ± SEM of JVM-2 following pre-treatment with vehicle, AA 35 μM,
EPA 50 μM or DHA 50 μM alone and following treatment with 1.5 μM doxorubicin or 100 nM vincristine. Pre-treatment with DHA alone induced
significantly greater cell death as compared to vehicle. Compared to vehicle, Cells pre-treated with DHA had significantly greater cell death when
treated with doxorubicin or vincristine. Figure 3D provides 2D graphical representations of Annexin-V/PI Plots. ‘Early’ Apoptosis was defined as
cells positive for Annexin-V-FITC only. ‘Late’ Apoptosis was defined as cells positive for Annexin-V-FITC and PI. ‘Necrotic’ was defined as cells
positive for PI only.Statistical significance was determined by Multiple Comparison Test with Dunnet’s correction (Figure 3A and B) or Tukey’s
correction (Figure 3C). α = 0.05, * <0.05, ** < 0.01, *** < 0.001.
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creased viability of cells treated with vincristine.
Pre-treatment of cells with AA, EPA or DHA did not
increase the sensitivity of MEC-2 to fludarabine(data not
shown).
Figure 4C illustrates the % dead cells ± SEM of MEC-2 in
the presence or absence of vehicle, AA, EPA, or DHA alone
and following treatment with doxorubicin (1.5 μM) or vin-
cristine (100 nM). Compared to vehicle, cells pre-treatedwith DHA alone had significantly higher cell death; whereas
cells pre-treated with either AA or EPA had significantly
less cell death. The addition of doxorubicin or vincristine
to DHA pre-treated cells induced higher cell death as com-
pared to vehicle; however, this was only significant when
compared to AA pre-treated cells. Figure 4D displays a
graphical 2D representation of Annexin-V/PI plots of
MEC-2 cells pre-treated with either vehicle or DHA and
following treatment with doxorubicin or vincristine.
MEC-2
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Figure 4 In vitro sensitivity of MEC-2 following treatment with doxorubicin or vincristine in the presence and absence vehicle, AA, EPA
or DHA. Cell viability was determined by MTT assay. Percent (%) cell death was determined by Annexin-V/Propidium Iodide duel stain with flow
cytometry. Figure 4A illustrates the % cell viability ± SEM of MEC-2 to doxorubicin (0–7.5 μM) in the presence or absence of vehicle, AA 25 μM,
EPA 50 μM or DHA 50 μM. Cells pre-treated with either EPA or DHA had significantly greater decreases in cell viability as compared to vehicle
when treated with doxorubicin. Figure 4B illustrates the % cell viability ± SEM of MEC-2 to vincristine (0-250 nM) in the presence or absence of
vehicle, AA 25 μM, EPA 50 μM or DHA 50 μM. Cells pre-treated with either EPA or DHA had significantly greater decreases in cell viability as
compared to vehicle following treatment with vincristine. Figure 4C illustrates the % dead cells ± SEM of MEC-2 following pre-treatment with
vehicle, AA 25 μM, EPA 50 μM or DHA 50 μM alone and following treatment with 1.5 μM doxorubicin or 100 nM vincristine. Compared to vehicle,
pre-treatment DHA alone induced significantly greater cell death; whereas pre-treatment with either AA or EPA induced significantly lower cell
death. Cells pre-treated with DHA had higher cell death, as compared to vehicle, when treated with doxorubicin or vincristine; however, this was
only significant when compared against AA pre-treated cells. Figure 4D provides 2D graphical representations of Annexin-V/PI Plots. ‘Early’
Apoptosis was defined as cells positive for Annexin-V-FITC only. ‘Late’ Apoptosis was defined as cells positive for Annexin-V-FITC and PI. ‘Necrotic’
was defined as cells positive for PI only. Statistical significance was determined by Multiple Comparison Test with Dunnet’s correction (Figure 4A
and B) or Tukey’s correction (Figure 4C). α = 0.05, * <0.05, ** < 0.01, *** < 0.001.
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induce G2/M arrest
We wanted to determine whether increased chemo-
sensitivity by FA was also associated with enhanced
growth-inhibition; thus, we performed a cell-cycle analysis.
Inhibition of cell-cycle progression leads to growth-
inhibition (reduced proliferation).Table 1 illustrates the mean G1/G2 ratio ± SEM of all
three cell lines in the presence of vehicle, AA, EPA or
DHA alone and following treatment with 1.5 μM doxo-
rubicin (EHEB, JVM-2, MEC-2), 40 μM fludarabine
(EHEB), or 100 nM vincristine (JVM-2, MEC-2). Cell
cycle analysis was not performed on EHEB following
treatment with vincristine or on JVM-2 and MEC-2
Table 1 Pre-treatment with FAs alone and following treatment with doxorubicin, vincristine or fludarabine
induces G2/M arrest
Table 1. Cell cycle analysis: G1/G2 ratio
EHEB
Control ± SEM Vehicle ± SEM p-value AA25 μM± SEM p-value EPA50 μM± SEM p-value DHA75 μM± SEM p-value
(-) Drugs 4.1 ± 0.09 4.3 ± 0.04 NS 3.7 ± 0.8 NS 4.0 ± 0.50 NS 4.2 ± 0.20 NS
(+) 1.5 μM Dox 9.2 ± 0.21 9.0 ± 0.27 NS 9.5 ± 0.32 NS 8.9 ± 0.72 NS 5.8 ± 0.77 <0.05
(+) 40 μM Flud 13.3 ± 0.21 15.5 ± 0.04 NS 13.5 ± 0.19 NS 11.6 ± 2.08 NS 4.9 ± 0.22 <0.01
JVM-2
Control ± SEM Vehicle ± SEM p-value AA35 μM± SEM p-value EPA50 μM± SEM p-value DHA50 μM± SEM p-value
(-) Drugs 2.4 ± 0.14 2.4 ± 0.04 NS 2.2 ± 0.06 NS 1.8 ±0.12 NS 1.8 ± 0.09 <0.05
(+) 1.5 μM Dox 2.9 ± 0.16 3.1 ± 0.18 NS 2.6 ± 0.00 NS 2.6 ± 0.07 NS 2.18 ± 0.23 <0.05
(+) 100 nM Vin 1.2 ± 0.00 1.2 ± 0.02 NS 0.9 ± 0.00 <0.05 0.8 ± 0.01 <0.01 0.9 ± 0.06 <0.05
MEC-2
Control ± SEM Vehicle ± SEM p-value AA25 μM± SEM p-value EPA50 μM± SEM p-value DHA50 μM± SEM p-value
(-) Drugs 5.2 ± 0.29 4.8 ± 0.10 NS 4.9 ± 0.37 NS 3.6 ± 0.14 <0.05 2.8 ± 0.28 <0.001
(+) 1.5 μM Dox 3.0 ± 0.11 2.8 ± 0.23 NS 1.5 ± 0.08 <0.001 1.12 ± 0.10 <0.001 1.1 ± 0.15 <0.001
(+) 100 nM Vin 1.2 ± 0.07 1.4 ± 0.19 NS 0.7 ± 0.06 <0.05 0.6 ± 0.04 <0.01 0.9 ± 0.18 NS
Table 1 illustrates the G1/G2 ratios ± SEM of EHEB, JVM-2 and MEC-2 following treatment with 1.5 μM doxorubicin, 100 nM vincristine or 40 μM fludarabine in the
presence or absence of vehicle, AA, EPA or DHA. Treatment with DHA alone indicated significantly lower ratios of G1/G2, indicative of G2/M arrest, as compared
to vehicle in all three cell lines. Treatment with EPA indicated a significantly lower G1/G2 ratio as compared to vehicle in MEC-2. Pre-treatment with AA, EPA or
DHA indicated significantly lower G1/G2 ratios as compared to vehicle following treatment with doxorubicin or vincristine. Only pre-treatment with DHA indicated
a significantly lower G1/G2 ratio as compared to vehicle following treatment with fludarabine in EHEB. Statistical significance was determined by Multiple
Comparison Test using Tukey’s correction. Abbreviations: Dox: doxorubicin, Vin: Vincristine, Flud: Fludarabine. α = 0.05, NS= not significant.
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significant differences in the in vitro sensitivity of these
cell lines to these drugs in the presence AA, EPA or
DHA as compared to vehicle.
FA treatment alone: A significantly lower G1/G2 ratio
indicates G2/M arrest. Treatment with EPA alone in-
duced a significantly lower G1/G2 ratio, as compared to
vehicle in MEC-2 (p: <0.05). Treatment with DHA alone
induced a significantly lower G1/G2 ratio as compared
to vehicle in JVM-2 and MEC-2 (p: <0.05 and <0.001;
respectively). Treatment with AA alone did not induce
any significant differences in the G1/G2 ratio as com-
pared to vehicle in EHEB, JVM-2 or MEC-2.
FA plus drug treatment: Cells pre-treated with AA had
significantly lower G1/G2 ratios as compared to vehicle
when treated with doxorubicin (p: <0.001 in MEC-2) or
vincristine (p: <0.05 and <0.05 in JVM-2 and MEC-2,
respectively).
Cells pre-treated with EPA had significantly lower G1/G2
ratios as compared to vehicle when treated with doxorubi-
cin (p: <0.001 in MEC-2) or vincristine (p: <0.01 in JVM-2
and MEC-2). Cells pre-treated with DHA had significantly
lower G1/G2 ratios as compared to vehicle when treated
with doxorubicin (p: <0.05, <0.05, and <0.001 in EHEB,
JVM-2 and MEC-2, respectively), fludarabine (p: <0.01 in
EHEB), or vincristine (p: <0.05 and <0.001 in JVM-2 and
MEC-2, respectively).N-3 increases generation of intracellular ROS
To investigate ROS production in response to AA, EPA
or DHA alone and following treatment with doxorubicin
or fludarabine we used a CM-H2DCFDA probe.
Figure 5A illustrates mean relative fluorescence units
(RFU) ± SEM across time for MEC-2. Of the 3 cell types,
ROS were increased only in MEC-2 cells due to pre-
treatment with either EPA or DHA. Linear regression
analysis indicated that the rate of increase in ROS was
significantly greater in DHA pre-treated MEC-2 cells
than in vehicle pre-treated cells (Mean slope (RFU)/min:
0.683 versus 0.267, p: <0.01). Similarly, the rate of in-
crease in ROS was greater in the presence of EPA than
in vehicle treated MEC-2 cells (Mean slope (RFU)/min:
0.483 versus 0.267, p: 0.08); however this was not statis-
tically significant. Pre-treatment with AA did not induce
any differences in the levels of ROS as compared to
vehicle.
There were no differences in levels of ROS for EHEB
or JVM-2 in the presence of AA, EPA or DHA as com-
pared to vehicle (data not shown). Pre-treatment with
vehicle, AA, EPA or DHA followed by treatment with
doxorubicin or fludarabine did not induce any signifi-
cant changes in levels of ROS as compared to vehicle or
FA alone in any of the cell lines (data not shown). ROS
production in the presence of vincristine was not per-
formed.
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Lipid Peroxidation
Figure 5 Chemo-sensitizing capability of DHA is mediated through generation of intracellular ROS and formation of lipid peroxides.
Figure 5A illustrates mean relative fluorescence units ± SEM of MEC-2 over the course of 2 hours following 72 hour pre-treatment with vehicle,
AA 25 μM, EPA 50 μM or DHA 50 μM. Linear regression analysis indicated a greater slope following treatment with EPA or DHA versus vehicle
(0.483 and 0.683 versus 0.267) indicating an increased generation of ROS across time. Figure 5B illustrates mean ng MDA/μg protein ± SEM in the
presence or absence of vehicle, AA 25 μM, EPA 50 μM or DHA 50 μM alone and following treatment with doxorubicin (1.5 μM) or vincristine
(100 nM). Pre-treatment with DHA induced significantly higher levels of MDA as compared to vehicle. The addition of doxorubicin to DHA
pre-treated cells induced significantly higher levels of MDA versus either alone. The addition of vincristine to either EPA or DHA pre-treated cells
induced significantly lower levels of MDA as compared to n-3 or drug alone. Figure 5C illustrates the % cell viability ± SEM of MEC-2 following
treatment with 1.5 μM doxorubicin and 50 μM vitamin-E alone and in combination in the presence or absence of vehicle, AA 25 μM, EPA 50 μM
or DHA 50 μM. Compared to vehicle, cells pre-treated with DHA had significantly greater reductions in cell viability when treated with
doxorubicin. Co-treatment of DHA pre-treated cells with doxorubicin and vitamin-E abrogated the enhanced sensitivity of MEC-2 to doxorubicin
by DHA. Figure 5D illustrates mean ng MDA/μg protein ± SEM of MEC-2 following pre-treatment with DHA alone and after treatment with 1.5 μM
doxorubicin alone and in combination with 50 μM vitamin-E. Co-treatment with doxorubicin and vitamin-E in DHA pre-treated cells indicated
significantly lower levels of MDA versus doxorubicin alone. Statistical significance was determined by Multiple Comparison Test with Tukey’s
correction. Abbreviations: MDA: malondialdehyde, α = 0.05, * <0.05, ** < 0.01, *** < 0.001.
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To investigate the formation of lipid peroxides in response
to AA, EPA or DHA treatment alone and with doxorubi-
cin, fludarabine or vincristine, levels of thiobarbituric acid
reactive substances (TBARS, byproducts of lipid peroxida-
tion) were evaluated and compared to a malondialdehyde
(MDA, (a TBARS)) standard curve. Figure 5B illustratesthe mean ng MDA/μg of protein ± SEM of MEC-2 treated
in the presence of vehicle, AA, EPA or DHA alone and
following treatment with 1.5 μM doxorubicin or 100 nM
vincristine. Pre-treatment of MEC-2 cells with DHA alone
induced significantly higher levels of TBARs than did ve-
hicle. Only DHA pre-treatment induced significantly
higher levels of TBARs in doxorubicin treated cells. Cells
Fahrmann and Hardman Lipids in Health and Disease 2013, 12:36 Page 9 of 13
http://www.lipidworld.com/content/12/1/36pre-treated with either EPA or DHA had significantly
lower levels of TBARs when treated with vincristine as
compared to the FA alone. Analysis of TBARs levels fol-
lowing treatment with fludarabine were not performed as
no statistical differences were found in the in vitro sensi-
tivity trials. EHEB and JVM-2 had similar trends in levels
of TBARs following n-3 pre-treatment as observed in
MEC-2; however, the drug treatment did not induce any
significant differences as compared to vehicle or n-3 alone
(data not shown).
Vitamin E abrogates enhanced sensitization of MEC-2 to
doxorubicin by DHA
To validate that the ability of n-3 to sensitize malignant
B-lymphocytes to doxorubicin is dependent on the for-
mation of toxic lipid peroxides, we tested the in vitro
sensitivity of MEC-2 in the presence of vehicle, AA, EPA
or DHA alone and following treatment with 1.5 μM
doxorubicin alone or in combination with 50 μM vita-
min E. Figure 5C illustrates the in vitro sensitivity of
MEC-2 to 1.5 μM doxorubicin and 50 μM vitamin E
alone and in combination in the presence or absence of
vehicle, AA, EPA or DHA. Compared to vehicle, DHA
pre-treated cells had significantly greater reductions in
viability when treated with doxorubicin. The addition of
vitamin E abrogated the enhanced sensitization of MEC-
2 to doxorubicin by DHA. In agreement with the
in vitro sensitivity trial, co-treatment of DHA pre-
treated cells with doxorubicin and vitamin E induced
significant reductions in the levels of TBARs as com-
pared to doxorubicin alone (Figure 5D).
Discussion
Chronic lymphocytic leukemia is the most common
form of adult leukemia in the western world [1]. Clinical
treatment of CLL is often limited due to drug resistance
and severe toxicities associated with chemotherapy [1-3].
A therapeutic intervention that could enhance the sensi-
tivity of CLL cells to anti-cancer drugs without causing
additional adverse effects would be clinically beneficial.
Omega 3 fatty acids have consistently been shown to
enhance the sensitivity of various solid tumor cells to
chemotherapy in vitro [7,8] and in vivo [9-11]. However,
this has not been shown in CLL. Previous results from
our group indicated that consumption of an n-3 supple-
ment enhanced the sensitivity of lymphocytes isolated
from patients with early stage (Rai 0,1) CLL to doxorubi-
cin in an in vitro assay [12]. These findings prompted us
to further evaluate the potential use of n-3 as chemo-
sensitizing agents for the treatment of CLL.
The primary purpose of this study was to illustrate
that pre-treatment of B-CLL-and B-PLL-derived cells
with n-3 increases the sensitivity of cells to actively usedchemotherapeutic drugs: doxorubicin and vincristine,
components of the CHOP (cyclophosphamide, doxo-
rubicin, vincristine and prednisone) regimen [16,17], or
fludarabine, a commonly used first-line treatment option
for CLL [1,2]. Rather than testing combination therapies,
we evaluated the ability of n-3 to enhance the sensitivity
of malignant B-lymphocytes to single-arm treatments.
Secondary objectives were to elucidate potential mech-
anism(s) by which n-3 enhanced chemo-sensitivity.
Although designated as a single disease, CLL is charac-
terized by biological and clinical heterogeneity. For these
reasons, we particularly wanted to demonstrate that the
chemo-sensitizing effects of n-3 were not limited to one
specific cell sub-type (cell line). Rather we wanted to
demonstrate that the chemo-sensitizing effects of n-3
would be seen in multiple cell-types. Thus, each cell line
could be viewed as a distinct case of CLL.
For the purposes of this study, we used the highest
concentrations FAs that alone did not induce significant
cytotoxicity (Figures 1A-C). Our results indicated that
clinically achievable concentrations of EPA and DHA
generally, but not equally, sensitized the B-leukemic cells
to the drugs. Only JVM-2 cells were sensitized to doxo-
rubicin (1.5 μM) when cells were pre-treated with AA
(Figure 3A), indicating that the chemo-sensitizing cap-
abilities of FAs are more likely to be found amongst n-3
fatty acids than n-6 fatty acids. This is an important con-
sideration. The western diet is heavily favored towards
n-6 FA with little to no n-3 FA intake [5,6]. Omega 3
and n-6 FAs compete with each other for incorporation
into the cell [5,6]. The addition of n-3 as an augment to
therapy may, therefore, provide clinical benefit to the pa-
tient receiving therapy. We are currently conducting a
clinical trial to determine if we will see the same chemo-
sensitizing capabilities of n-3 on lymphocytes isolated
from patients with CLL.
We have illustrated that pre-treatment with n-3 in-
creased the sensitivity of B-CLL- and B-PLL-derived cells
to three actively used chemo-therapeutic drugs. While
doxorubicin, vincristine and fludarabine have different
mechanisms by which they exert their cytotoxic effects, all
three drugs can induce cell death and/or growth-
inhibition. Thus, increasing the sensitivity of cells to the
drug is not a function limited to increased cell death, but
can also be mediated through increased growth-inhibition
(reduced proliferation). Both cell death and/or growth-
inhibition leads to a decrease in numbers of viable cells in
culture. For these reasons, we performed Annexin-V as-
says, as a measure of cellular death, and cell cycle analyses,
as an indirect measure of growth (proliferation). Increased
cell death and/or increased growth-inhibition are clinically
relevant and would provide benefit to the patient.
Collectively, our results indicated that pre-treatment
with DHA, as compared to vehicle, enhanced cell death
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(JVM-2 and MEC-2) of the three cell lines, and flu-
darabine in one (EHEB) of the three cell lines. Increased
cell death is clinically beneficial and would improve the
outcome of the patient receiving therapy.
Noteworthy, MEC-2, which harbors a p53 mutation,
showed enhanced cell death due to vincristine or doxo-
rubicin when pre-treated with DHA as compared to ve-
hicle. This is an important observation. The loss of short
arm p13 of chromosome 17, which disrupts the p53 tumor
suppressor gene, is found in approximately 5-10% of all
CLL patients and is associated with particularly poor prog-
nosis and chemorefractoriness [18]. N-3 may provide a
beneficial augment to the treatment of chemorefractory
CLL patients.
We performed cell-cycle analyses to determine
whether increased chemo-sensitivity by FA was associ-
ated with enhanced growth-inhibition. Previous studies
have demonstrated that n-3 treatment alone can induce
cell cycle arrest at the G2/M phase [19]. Vincristine is a
mitotic inhibitor known to induce cell cycle arrest at the
M phase [20]. Similarly, studies have indicated that ma-
lignant cells in G2/M arrest are more sensitive to doxo-
rubicin than normal cells [21,22]. For these reasons, we
were particularly interested in the ratio of cells in G1
(G0 + G1) and G2 (G2 +M) phases. An increase in the
population of cells in the G2 (G2 +M) phase is indicative
of G2/M arrest. Thus, an increase in G2 (G2 +M) would
result in a lower population of cells in G1 (G0 +G1) and a
lower G1/G2 ratio. A decrease in the G1/G2 ratio (indi-
cative of G2/M arrest) would be expected to result in
growth-inhibition (reduced proliferation).
Our results illustrate that cells pre-treated with n-3,
but without drug, had significantly greater G2/M arrest,
indicated by a lower G1/G2 ratio, as compared to vehicle
pre-treated cells (Table 1). This demonstrates that n-3
by themselves can potentially slow the growth of malig-
nant B-lymphocytes. This is of considerable interest as
we had previously shown that consumption of n-3 de-
creased the activity of nuclear factor kappa B (NFκB) in
isolated lymphocytes of patients with early stage CLL
and would be expected to slow the progression of the
disease [12]. Studies have shown that inhibition of NFκB
activation leads to cell cycle arrest at the G2/M phase
aiding to both growth-inhibition and cell death [23,24].
Future studies will be aimed in determining if n-3 can
slow the progression and growth of CLL and whether
growth-inhibition is mediated through suppression of
NFκB activation and G2/M arrest. Slowing the progres-
sion of CLL by n-3 FAs could be a therapeutic choice in
patients for whom standard chemotherapy is not an
option.
The addition of doxorubicin to FA pre-treated cells in-
duced significantly greater G2/M arrest than when cellswere not treated with n-3 prior to doxorubicin (Table 1).
It is interesting to note that cells pre-treated with either
EPA (MEC-2) or DHA (EHEB, JVM-2 and MEC-2)
which had significantly greater G2/M arrest due to
doxorubicin also showed increased chemo-sensitivity to
doxorubicin than did cells pre-treated with vehicle
(Figures 2A, 3A and 4A). This suggests that n-3 plus
doxorubicin induced greater growth-inhibition than
doxorubicin alone. This notion is supported by other in-
vestigators who have shown that cells in G2/M arrest
are more sensitive to doxorubicin as compared to normal
cells [21,22] and, importantly, that enhanced sensitivity of
cells in G2/M arrest to doxorubicin was mediated through
both growth-inhibition and apoptosis [22].
Similarly, the addition of vincristine (JVM-2 and
MEC-2) or fludarabine (EHEB) to cells pre-treated with
certain FAs (all FAs in JVM-2, AA and EPA in MEC-2,
DHA in EHEB) had significantly greater G2/M arrest as
compared to vehicle pre-treated cells (Table 1). However,
there was no association between the increase in chemo-
sensitivity of cells to vincristine (JVM-2 and MEC-2) or
fludarabine (EHEB) by FA and the increase in G2/M
arrest.
Numerous pre-clinical studies have demonstrated that
enhanced chemo-sensitization by n-3, particularly DHA,
was dependent on the formation of toxic lipid peroxides
and generation of ROS [7,11,25-28]. We wanted to de-
termine whether the increase in chemo-sensitivity of
cells to the anti-cancer drugs by FA was dependent on
the induction of oxidative stress. Our results illustrate
that n-3 induced significantly higher levels of intracellu-
lar ROS than did vehicle in MEC-2 cells (Figure 5A).
Linear regression analysis indicated an increased rate of
ROS generation in the presence of either EPA or DHA
as compared to vehicle. However, this effect was not en-
hanced by the addition of any of the anti-cancer drugs.
Results also illustrate that treatment with n-3 alone
induced higher levels of TBARS, (products of lipid
peroxidation), as compared to vehicle in all three cell
lines (only MEC-2 is shown, Figure 5B). Only MEC-2
had significantly higher levels of TBARs following
treatment with doxorubicin in cells pre-treated with
DHA as compared to cells treated with DHA or
doxorubicin alone (Figure 5B). The addition of vita-
min E, a fat soluble anti-oxidant, abrogated the en-
hanced sensitivity of MEC-2 to doxorubicin by DHA
(Figure 5C) and decreased the levels of TBARS
(Figure 5D). The fact that enhanced sensitivity of
MEC-2 to doxorubicin by DHA and increased formation
of TBARs was abrogated by vitamin E supports the notion
that enhanced chemo-sensitivity by DHA is, in part,
dependent on the formation of lipid peroxides.
In conclusion, EPA and DHA differentially sensitized
B-leukemic cell lines EHEB, JVM-2 and MEC-2 to
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hanced chemo-sensitivity is likely mediated through
both increased cellular death as well as growth-
inhibition. Our results have shown that enhanced sensi-
tivity is also, in part, dependent on the formation of
toxic lipid peroxides. Additional work should be done to
elucidate the mechanisms by which n-3 increase chemo-
sensitivity. Supplementation of the diet with n-3 fatty
acids provides a promising non-toxic approach to not only
sensitize CLL cells to anti-cancer drugs but may have in-
dependent therapeutic benefit. Importantly, the chemo-
sensitizing effects of n-3 do not appear to be limited to a
specific cell-type or a specific drug. Increased chemo-
sensitivity is clinically beneficial and would be expected to
increase drug efficacy, and potentially reduce drug dosage
resulting in decreased drug-induced toxicities.
Materials and methods
Chemicals
Ninety-five percent pure doxorubicin hydrochloride (Fisher
Scientific), and 2-fluoroadenine-9-β-D-arabinofuranoside
(Sigma Aldrich) were dissolved in dimethyl sulfoxide
(DMSO) to stock solutions and diluted to the working
concentrations in cell type specific culture media. Vincris-
tine sulfate salt (Sigma Aldrich) was dissolved in ddH2O
to stock solutions and diluted to the working concen-
trations in cell type specific culture media. Vitamin E
(α-tocopherol) (Sigma Aldrich) was dissolved in ethanol
to stock solutions and diluted to working concentrations
in the cell type specific media.
Cell lines
EHEB (B-CLL), JVM-2 and MEC-2 (B-Prolymphocytic
Leukemia) were obtained from Deutsche Sammlung von
Mikroorganismen und Zellkulturen (DSMZ). Cells were
grown in 1640 RPMI (ATCC) (EHEB and JVM-2) or
Iscove’s Modified Dulbecco’s Medium (HyClone, Thermo
Scientific) (MEC-2) supplemented with 10% Fetal Bovine
Serum (HyClone, Thermo Scientific), 100 units/mL peni-
cillin and 0.1 mg/mL streptomycin. All cell lines were
grown in humidified incubator at 37°C and 5% CO2.
Fatty acid treatments
Stock solutions of 100 mM eicosapentaenoic acid (EPA),
docosahexaenoic acid (DHA) or arachidonic acid (AA)
(Cayman Chemical) in ethanol were made and diluted to
the working concentrations in cell type specific culture
media. Fatty acid concentrations used represent the con-
centration of each fatty acid that alone did not induce
significant cytotoxicity. One million five hundred thou-
sand (1.5×106) cells per well were seeded in a 6 well
plate (Santa Cruz Biotechnology, Inc) and treated with
vehicle (ethanol only), AA, EPA or DHA at the sta-
ted concentration for 72 hours. Cells were treated for72 hours with FA to allow adequate time for FA incorp-
oration and to allow for any FA-dependent changes in
cellular function. Chosen concentrations of FA are clin-
ically achievable [12]. Post 72 hours, cells were counted
with a hemocytometer and prepared for the assays
below.
Lipid composition
Fatty acid composition was assessed by gas chromato-
graphy according to our routine techniques [29]. Post
72 hours, cells were washed twice with 1X PBS. Cells were
subsequently homogenized in distilled water with 0.1%
BHT to prevent fatty acid oxidation. Lipids were extracted
with chloroform/methanol, and then methylated. Methy-
lated lipids were separated and identified using gas chro-
matography as previously published [29]. Fatty acid
methyl ester standards (Nu-Chek-Prep, Elysian, MN) were
used for peak identification.
Sensitivity trials
Cell counts were performed and viability was determined
by Trypan Blue Exclusion assay following 72 hour fatty
acid treatments (FA). Approximately 1x105 living cells/well
were seeded in triplicate into a round bottom 96 well plate
(CELLSTAR, Greiner Bio One International AG). Cells
were subsequently treated with culture media containing
DMSO, H2O (solvent controls), doxorubicin (0–7.5 μM),
vincristine (0-250 nM) or fludarabine (0-50 μM) without
FA for 20 hours (doxorubicin) or 24 hours (vincristine,
fludarabine). Cells were treated in the presence or absence
of 50 μM vitamin E alone and in combination with do-
xorubicin (1.5 μM) after 72 hour FA pre-treatment for
Vitamin E rescue trials. Cell viability was determined
using colorimetric MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) (CALBIOCHEM, EMD
MILLIPORE) assay. Cell viability was assessed by measu-
ring the intensity of precipitate formed, relative to control
specimens. Absorption was measured using a SpectraMax
M2 (Molecular Devices, Sunnyvale, CA) spectrophotom-
eter at 570 nm. All measurements obtained from the MTT
assay following treatment with the anti-cancer drugs in the
presence of vehicle, AA, EPA or DHA were compared to
cells treated with the vehicle or FA alone. MTTassays were
performed in technical and biological triplicate.
Measurement of apoptosis by annexin-V/propidium
iodide duel stain
Apoptosis was measured by duel stain immunofluores-
cence flow cytometry. Briefly, post 72 hour FA treatments,
cell counts were performed and approximately 5 × 105
cells were treated in the presence of DMSO, H2O (solvent
controls), doxorubicin (1.5 μM), vincristine (100nM) or
fludarabine (40 μM) as previously described under sensi-
tivity trials. Cells were washed twice with cold 1X PBS and
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100 μL of Annexin-V binding buffer (0.01 M HEPES,
0.14 M NaCl, 2.5 mM CaCl2), 1 μL Annexin-V Alexa
Fluor 488-Conjugate (Invitrogen), and 10 μg/mL pro-
pidium iodide (Sigma Aldrich). Cells were analyzed using
an Accuri Flow Cytometer. ‘Early’ Apoptosis was defined
as cells positive for Annexin-V-FITC only. ‘Late’Apoptosis
was defined as cells positive for Annexin-V-FITC and
Propidium Iodide (PI). ‘Necrotic’ was defined as cells po-
sitive for PI only (Equation 1). Total% cell death was de-
fined as the sum population of cells in early apoptosis, late
apoptosis and necrosis. Annexin-V assays were performed
in biological triplicate.
Equation 1: Total % Cell Death
¼ ð% NecroticÞ þ ð% Late ApoptosisÞ
þ ð% Early ApoptosisÞ
Cell cycle analysis
Post 72 hour FA treatments, cells were counted and ap-
proximately 1 × 106 cells were treated in the presence of
DMSO, H2O (solvent controls), doxorubicin (1.5 μM),
vincristine (100nM) or fludarabine (40 μM) as previously
described under sensitivity trials. Cells were subse-
quently washed twice with cold 1X PBS and resuspended
in DNA staining buffer containing 0.2% Triton X-100,
0.2% Na3-Citrate, 30 μg/mL RNase and 20 μg/mL pro-
pidium iodide (Sigma Aldrich) or DNA staining buffer
without propidium iodide to serve as negative controls.
Cells were incubated for 30 minutes in the dark at room
temperature and subsequently analyzed using an Accuri
Flow Cytometer. Cell cycle analyses were performed in
biological triplicate. Calculation of G1/G2 ratio is des-
cribed in equation 2.Equation 2: G1=G1 Ratio
¼ ð# of events in G0 þ G1Þ=ð# of events in G2 þ MÞ
Lipid peroxidation
Lipid peroxidation was measured by means of thiobar-
bituric acid reactive substances (TBARS) assay. Briefly,
approximately 1 to 1.5 × 106 cells were collected in 600 μL
1X PBS post 72 hour fatty acid treatments as described
under fatty acid treatments and after doxorubicin
(1.5 μM) or vincristine (100 nM) or fludarabine (40 μM)
alone or in combination with 50 μM vitamin E (doxorubi-
cin only). Cells were sonicated 2X on 10 second intervals
at 40 V setting over ice using a Fisher Scientific Sonic
Dismembrator. TBARS assay (Cayman Chemical), in bio-
logical triplicate, was performed according to protocol
and reported as ng of malondialdehyde/μg of protein.
Intracellular ROS generation
Levels of intracellular ROS were determined using
5-(and-6-)chloromethyl-2’,7’-dichlorodihydro-fluorescein
diacetate, acetyl ester (CM-H2DCFDA) (Invitrogen).
Briefly, post 72 hour fatty acid treatments, one hundred
thousand (105) live cells were seeded in triplicate into a
round bottom 96 well plate (CELLSTAR, Greiner Bio
One International AG). Cells were washed twice with 1X
Dulbecco’s PBS (DPBS) (GIBCO, Invitrogen) and incu-
bated for 60 minutes in the presence or absence of
10 μM CM-H2DCFDA in Dulbecco’s Modified Eagles
Medium (DMEM, Thermo Scientific) (SIGMA) without
FBS containing 100 units/mL pencillin, 0.1 mg/mL strep-
tomycin. Post 60 minute incubation, cells were washed 2X
with 1X DPBS and treated in the presence or absence of
DMSO, doxorubicin (1.5 μM), or fludarabine (40 μM)
where after cell suspensions were transferred to a 96 well
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Fluorescence was measured every 10 minutes for 2 hours
using SpectraMax M2 spectrophotometer (Molecular
Devices, Sunnyvale, CA) at 480 nm excitation 530 nm
emission. Assays for intracellular ROS generation
were performed in technical triplicates and biological
duplicates.Statistical analysis
Prism© software (Graphpad, Inc., La Jolla, CA) was used
for statistical analysis of numeric data by Multiple Com-
parison using appropriate Post-Hoc Test and for linear
regression analyses. Prism© software (Graphpad, Inc., La
Jolla, CA) was used for preparation of graphs. Statistical
significance on Annexin-V assays is based on total% cell
death as described in equation 1.
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